Quantitative proteomics reveal three potential biomarkers for risk assessment of acute myocardial infarction

Bioengineered. 2022 Mar;13(3):4939-4950. doi: 10.1080/21655979.2022.2037365.

Abstract

Acute myocardial infarction (AMI) is the one of the main cause of death worldwide. Exosomes carry important information about intercellular communication and could be diagnostic marker for many diseases. Here, we aimed to find potential key proteins for the early diagnosis of AMI. A label free proteomics strategy was used to identify the differentially expressed proteins (DEPs) of AMI patients' plasma exosome. By bioinformatics analysis and enzyme-linked immunosorbent assay to validate the candidate proteins. Compared to healthy control plasma exosome, we totally identified 72 differentially expressed proteins (DEPs) in AMI patients. Also, we found that complement and coagulation cascades was activated by KEGG analysis and GSEA. PLG, C8B and F2 were selected as candidate molecules for further study, and then validated another 40 plasma samples using enzyme-linked immunosorbent assay. Finally, we found that the expression levels of these three proteins (PLG, C8B and F2) were significantly higher than those of healthy controls (P < 0.05). ROC analysis revealed that PLG, C8B and F2 had potential value for AMI early diagnosis. In conclusion, our study identified three potential biomarkers for AMI diagnosis. But there remains a need to further study the mechanism of the biomarkers.

Keywords: Proteomics; acute myocardial infarction; biomarker; exosome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Humans
  • Myocardial Infarction* / diagnosis
  • Myocardial Infarction* / metabolism
  • Proteomics*
  • ROC Curve
  • Risk Assessment

Substances

  • Biomarkers

Grants and funding

The work was funded by Science and Technology plan of Jiangxi Provincial Health Commission (No.20204236).